Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | PRKDC | P78527 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 7/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636410 | 1.00 | ALDH1A1 (0.65) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL436131 | 0.91 | ALDH1A1 (0.54) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL2915368 | 0.89 | ALDH1A1 (0.57) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL87864 | 0.88 | ALDH1A1 (0.52) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL1620757 | 0.88 | LMNA (0.56) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL31291730 | 0.86 | ALDH1A1 (0.48) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL15033540 | 0.86 | ALDH1A1 (0.53) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL20488498 | 0.85 | ALDH1A1 (0.69) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL856062 | 0.85 | ALDH1A1 (0.49) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL70785 | 0.85 | ALDH1A1 (0.49) | ALDH1A1KDM4ETSHRTDP1PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2005530823-A | — | — | 2005-10-13 | — | — | JP | claimed |
| US-20050215553-A1 | Hexahydropyridazine-3-carboxylic acid hydrazide and hydrazone derivatives, combinatorial libraries containing same, pharmaceutical compositions containing same and methods of preparation | AVENTIS PHARMA S.A. (FR) | 2005-09-29 | — | — | US | claimed |
| EP-1515953-A2 | NOVEL HEXAHYDRO-PYRIDAZINE-3-CARBOCYLIC ACID HYDRAZIDE OR HYDRAZONE DERIVATIVES, COMBINATORIAL LIBRARIES CONTAINING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR PREPARING SAME | Aventis Pharma S.A. (FR) | 2005-03-23 | — | — | EP | claimed |
| CN-1143843-C | Process for preparing trifluoromethyl sulfoacid 2-trimethylammonium-4,5-dimethoxy-benzaldehyde | 中国科学院上海原子核研究所 | 2004-03-31 | — | — | CN | claimed |
| WO-2003106431-A2 | NOVEL HEXAHYDRO-PYRIDAZINE-3-CARBOCYLIC ACID HYDRAZIDE OR HYDRAZONE DERIVATIVES, COMBINATORIAL LIBRARIES CONTAINING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR PREPARING SAME | AVENTIS PHARMA S.A. (FR) | 2003-12-24 | — | — | WO | claimed |
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-02-03 | — | — | US | disclosed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-12173018-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| CN-113518776-B | Benzothiophene compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2024-03-21 | — | — | US | disclosed |
| US-5079256-A | Administering to treat diseases of circulatory organs such as renal/cardiac insufficiency | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-01-07 | — | — | US | disclosed |
| US-5077406-A | Cyclization, deprotecting and salt formation | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-12-31 | — | — | US | disclosed |
| US-5017569-A | Cephalosporin derivatives | ICI PHARMA (FR) | 1991-05-21 | — | — | US | disclosed |
| US-4966904-A | DILUROGENITAL DISORDERS; DILATION OF NEOPHROVASCULAR TRACTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-10-30 | — | — | US | disclosed |
| EP-0346367-A1 | ARYL- AND ARYLOXY-SUBSTITUTED TERT.-ALKYLENAMINES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE IN PHARMACY | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-12-20 | — | — | EP | disclosed |
| US-4876261-A | UROGENITAL DISORDERS; NEPHROVASCULAR DILATORS; ACT ON DOPAMINE RECEPTOR | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 1989-10-24 | — | — | US | disclosed |
| WO-1988006580-A1 | ARYL- AND ARYLOXY-SUBSTITUTED TERT.-ALKYLENAMINES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE IN PHARMACY | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-09-07 | — | — | WO | disclosed |
| EP-0027993-A1 | 6-Fluorodihydroxyphenylalanines, a process for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215553-A1 | Hexahydropyridazine-3-carboxylic acid hydrazide and hydrazone derivatives, combinatorial libraries containing same, pharmaceutical compositions containing same and methods of preparation | HK1, ACE, CTSZ | ALDH1A1 448/4885KDM4E 2325/4885TSHR 4004/4885 |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1961/4885KDM4E 4235/4885TSHR 2748/4885 |
| US-12173018-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | ALDH1A1 2794/4885KDM4E 2087/4885TSHR 4262/4885 |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | ALDH1A1 4678/4885KDM4E 3663/4885TSHR 3853/4885 |
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, CHP1, FKBP8 | ALDH1A1 4764/4885KDM4E 4000/4885TSHR 2134/4885 |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, MTOR, FKBP14 | ALDH1A1 4631/4885KDM4E 3832/4885TSHR 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.